Rationale: Calcification of heart valve structures is the most common form of valvular disease and is characterized by the appearance of bone-like phenotypes within affected structures. Despite the clinical significance, the underlying etiology of disease onset and progression is largely unknown and valve replacement remains the most effective treatment. The SRY-related transcription factor Sox9 is expressed in developing and mature heart valves, and its function is required for expression of cartilage-associated proteins, similar to its role in chondrogenesis. In addition to cartilage-associated defects, mice with reduced sox9 function develop skeletal bone prematurely; however, the ability of sox9 deficiency to promote ectopic osteogenic phenotypes in heart valves has not been examined. Objective: This study aims to determine the role of Sox9 in maintaining connective tissue homeostasis in mature heart valves using in vivo and in vitro approaches. Methods and Results: Using histological and molecular analyses, we report that, from 3 months of age, Sox9 fl/؉ ;Col2a1-cre mice develop calcific lesions in heart valve leaflets associated with increased expression of bone-related genes and activation of inflammation and matrix remodeling processes. Consistently, ectopic calcification is also observed following direct knockdown of Sox9 in heart valves in vitro. Furthermore, we show that retinoic acid treatment in mature heart valves is sufficient to promote calcific processes in vitro, which can be attenuated by Sox9 overexpression. Key Words: heart valves Ⅲ calcification Ⅲ Sox9 Ⅲ extracellular matrix Ⅲ mouse model C alcification of heart valve structures affects more than 27% of the US population over 65 years of age and is the major contributor of heart valve malfunction. 1 Despite the clinical significance, little is known about the mechanisms that underlie this multifactorial disease. Treatment options for valve calcification are limited, and no known therapies prevent disease progression. 2 Normal heart valve function requires organization of differentiated cell types and specialized extracellular matrix (ECM) within the valve leaflet is arranged according to blood flow. 3 This defined tissue architecture provides the mechanical resilience and compressibility required to open and close the valve orifices effectively during the cardiac cycle. 4 In diseased heart valves, loss of ECM organization is associated with changes in mechanical properties, ultimately leading to dysfunction. 5, 6 One of the most striking alterations in valve ECM homeostasis is ectopic bone-like matrix mineralization observed in calcific valve disease. 7, 8 At the functional level, this histopathologic alteration results in stiffened leaflets, narrowing of the valve opening, and impaired blood flow. 9 The mechanisms that promote the onset and progression of heart valve calcification are not clear, but recent reports suggest a complex process involving molecular and cellular phenotypes shared with bone formation and chronic inflammation. 8 The contribution of these phenotypes in the onset and progression of calcific valvular disease is not known; however, studies have identified clinical risk factors including older age and hypercholesterolemia. 2 Recent reports have also shown that regulatory mechanisms common to osteogenesis play a major role in valvular calcification. 10 Expression of bone-associated genes, including Runx2, a transcription factor required for the osteoblast gene program, and downstream target genes, including Osteopontin and Osteonectin, is increased in calcified lesions of human heart valves. 7,10 -12 The mechanisms initiating ectopic osteogenic processes in heart valves are not known, but recent reports have implicated a genetic basis and therefore developmental origins. 9, [13] [14] [15] The diversified cell types and ECM that form the mature valve architecture are derived during embryogenesis from undifferentiated precursor cells of endocardial cushions. 16 -18 Following endothelial to mesenchymal transformation and cushion formation, valve precursor cells differentiate and secrete specialized ECM. 16, 19 The molecular mechanisms that regulate this process are not well defined but are likely essential for normal Original
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First identified for its essential role in chondrocyte differentiation, the transcription factor Sox9 is known to play parallel roles in promoting expression of cartilaginous matrix proteins in developing heart valve structures. 20, 22 In addition to cartilage defects, mice with reduced Sox9 function develop premature skeletal ossification, suggesting an opposing role in bone formation. 23, 24 The mechanisms of Sox9 deficiency during skeletogenesis are not clear, although SOX9 function is sufficient to inhibit RUNX2-mediated activation of osteogenic target genes. 25 Upstream regulators of Sox9 in cartilage and bone formation include retinoic acid (RA). 26 -28 RA treatment of chondrogenic cells in vitro leads to decreased Sox9 activity, associated with reduced expression of cartilage genes 28, 29 and significant increases in Runx2 and osteogenic processes. 30, 31 These studies suggest that RA and Sox9 signaling play pivotal roles in promoting cartilage and bone phenotypes. However, the potential for RA-Sox9 signaling to promote osteogenic processes in heart valve connective tissue is not known.
Previous studies have shown that heart valves from mice with targeted homozygous loss of Sox9 in Type II Collagen (Col2a1)-derived cells express diminished levels of cartilage-associated proteins, 20 and increased calcium deposition is observed on valves from viable heterozygotes (Sox9 fl/ϩ ;Col2a1-cre). 20 However, molecular, cellular, and functional analyses were lacking in this previous study. 20 Here, we report that Sox9 fl/ϩ ;Col2a1-cre mice develop calcific lesions within heart valve leaflets from 3 months of age with significant increases in bone-related genes and ECM remodeling and inflammatory processes. This osteogenic phenotype is recapitulated following direct Sox9 knockdown in heart valve explants. Furthermore, calcification in chick valve explants is promoted by RA treatment, which can be attenuated by Sox9 overexpression. These data suggest that Sox9 plays an important role in preventing calcific processes in normal heart valves and identifies RA-Sox9 signaling as a suitable pathway for therapeutic targets in the prevention and treatment of calcific valvular disease.
Methods

Sox9
fl/fl female mice 32 were bred with Col2a1-cre males (The Jackson Laboratory) 33 to generate heterozygous offspring at expected Mendelian ratios. Sox9 fl/ϩ ;Col2a1-cre mice and Sox9 fl/ϩ littermate controls were age-matched and subject to echocardiography as described. 21 Following functional analysis, hearts were dissected and RNA extracted from atrioventricular regions (containing the mitral and tricuspid valves) or whole hearts were fixed, cryoembedded, and sectioned for histological staining, in situ hybridization, and immunofluorescence as described. 20 Real time PCR-based TaqMan Low Density Array (TLDA) cards were used to quantitatively identify changes in mRNA transcript levels of target genes as described. 34 For in vitro studies, neonate mouse or embryonic day (E)10 chick mitral valve explants were treated with DMSO, 1 mol/L RA, adenovirus (Ad)-green fluorescent protein (GFP), Ad-Sox9, or Ad-Cre.
An expanded Methods section is available in the Online Data Supplement at http://circres.ahajournals.org.
Results
Generation of Mice With Targeted Reduction of Sox9 Function in Heart Valves
Our previous studies have shown that Sox9 is highly expressed during early stages of endocardial cushion development. 20 Using immunofluorescence, we also detect Sox9 expression in the mitral ( Figure 1A) , tricuspid, pulmonic (data not shown), and aortic valve ( Figure 1B ) leaflets during remodeling stages at E17.5. To determine the role of Sox9 in murine heart valves, we used a targeted approach using the Cre/loxP system. Breedings of Col2a1-cre with Rosa26R reporter mice reveal recombination by X-gal staining in a subset of cells along the edges of the mitral ( Figure 1C ), aortic ( Figure 1D ), tricuspid, and pulmonic valve leaflets (data not shown) from E15.5, consistent with Sox9 expression ( Figure 1A and 1B). 20 In heart valves from 3-monthold Sox9 fl/ϩ ;Col2a1-cre Ϫ/Ϫ (Sox9 fl/ϩ ) mice, Sox9 is expressed in cells throughout the valve leaflet ( Figure 1E ). However, following recombination in Sox9 fl/ϩ ;Col2a1-cre mice, Sox9 expression is moderately reduced along the edges of the valve leaflets (arrows, Figure 1F ) associated with Col2a1-derived cells (arrows, Figure 1C ). This is in comparison to adjacent nonrecombined cells (arrowheads, Figure 1F ) and cells along the edges of valves from cre-negative Sox9 fl/ϩ littermate controls ( Figure 1E ). PE-CAM staining indicates the endothelial cell layer ( Figure  1E and 1F). These data validate successful recombination of Sox9 in targeted cells. Figure  2D ), or decalcified with EDTA (data not shown), eliminates misidentification of pigmented melanocytes present in the valves (Figure 2F ), the area of calcium deposition did not significantly change with age, and differences compared to control mice were not observed ( Figure 2E and 2F). However, there is a trend toward increased lesion size with older age in Sox9 fl/ϩ ;Col2a1-cre mice ( Figure 2E ), although survival is comparable to controls at 12 months of age. These findings suggest that reduced Sox9 function in Col2a1-derived cells during development promotes calcium deposition in adult heart valve leaflets.
Increased Calcium Deposition in Heart Valve
Non-standard Abbreviations and Acronyms
Heart Valves From Sox9 fl/؉ ;Col2a1-cre Mice Show Increased Osteogenic Signaling and Inflammatory and ECM Remodeling Processes at Twelve Months of Age
Recent studies have described human calcific valvular disease as an active process associated with activation of regulatory pathways common to bone development and increased inflammatory processes and ECM remodeling. 7, 36 To identify similar processes in Sox9 fl/ϩ ;Col2a1-cre mice, high-throughput quantitative real-time PCR was performed using custom TLDA cards designed to identify changes in genes characteristic of advanced human heart valve calcification. 10, [37] [38] [39] [40] [41] [42] [43] In heart valves from 12-month-old Sox9 fl/ϩ ;Col2a1-cre mice, transcript levels of several bone-related genes are significantly increased over controls. Similar to previous observations in human calcific valvular disease, these include increased expression of Runx2 (2-fold), Osteonectin (1.8-fold), Osteopontin (8.7-fold), Osteoprotegerin (3.9-fold), and Smpd3 (1.9-fold) compared to Sox9 fl/ϩ littermate controls ( Figure 3A) . 12, 44 Online Table II shows ;Col2a1-cre mice compared to controls. This is indicated by increased expression of vascular cell adhesion molecule-1 (Vcam-1) (1.9-fold), a cell adhesion molecule involved in proinflammatory signal transduction 48 ; colony-stimulating factor 1 receptor (Csf1r) (1.6-fold), indicative of macrophage infiltration; and Toll-like receptor 2 (Tlr2) (2.1-fold), important in cytokine release in immune response ( Figure 4A ). 49, 50 Spatially, increases in Vcam-1 expression by immunostaining were observed throughout the valve leaflet (data not shown). Furthermore, increases in inflammation-related transcripts observed in Sox9 fl/ϩ ;Col2a1-cre mice are significantly higher at 12 months compared to 3 months of age. Valvular disease is frequently associated with ECM disorganization and excess collagen deposition, leading to fibrosis. 3 In Sox9 fl/ϩ ;Col2a1-cre mice, transcript levels of genes associated with tissue fibrosis 51, 52 are increased, including Col1a1 (1.9-fold), Col1a2 (1.7-fold), and Tenascin-C (ten-C) (4.3-fold) ( Figure 4B ). In addition, the matrix metalloproteinase inhibitor Timp1 is increased 4-fold, indicative of valve leaflet remodeling. Disorganized elastic fibers have previously been reported with calcified heart valves. 53 In valves from Sox9 fl/ϩ ;Col2a1-cre mice, changes in elastin transcript levels are not observed; however, mature elastic fibers appear fragmented and ectopically distributed throughout the valve leaflet in Sox9 fl/ϩ ;Col2a1-cre mice ( Figure 4C ), compared to parallel bundles localized along the atrial surface in controls ( Figure 4D ). Collectively, these findings indicate that increased calcium deposition observed in Sox9 fl/ϩ ;Col2a1-cre mice is associated with activation of osteogenic, inflammation, and ECM remodeling programs.
Knockdown of Sox9 in Mature Heart Valves In Vitro Promotes Calcific Phenotypes
To support in vivo findings and determine a direct role for Sox9 in promoting heart valve calcification, atrioventricular valve explants from neonate Sox9 fl/fl mice were infected with adenovirus targeting Cre recombinase (Ad-Cre) ( Figure 5C ) or Ad-GFP ( Figure 5B ) as a negative control. In association with a Ͼ2-fold knockdown of Sox9 expression, explants infected with Ad-Cre display 28% von Kossa reactivity ( Figure 5B and 5C ), compared with negligible levels observed in Ad-GFP controls (Ͻ5%) ( Figure 5A and 5C ), or explants from Sox9 ϩ/ϩ mice infected with Ad-Cre (data not shown). This increase in calcium deposition is associated with a significant increase in Osteopontin and a trend toward increased Runx2 expression. These data support a direct role for reduced Sox9 function in promoting calcific heart valve phenotypes.
RA Treatment Reduces Sox9 Expression and Promotes Osteogenic-Like Processes in Mature Chick Heart Valves
RA has previously been identified as an upstream regulator of Sox9 during cartilage and bone development. 27, 28 To determine similar roles in mature heart valves intact avian mitral valve explants were subject to RA treatment in vitro. At E10, avian heart valves express high levels of Sox9 26 and exhibit highly organized ECM patterning indicative of maturation. 3 Following 1 mol/L RA treatment for 48 hours, von Kossa staining reveals significantly increased calcium deposition (21.7%) compared to DMSO controls (2.9%) ( Figure 6A , 6B, and 6G). Furthermore, RA treatment is associated with significant decreases in Sox9 transcript levels (5.3-fold) ( Figure 6H) .
To determine the role of reduced Sox9 in RA-induced valve calcification, avian explants treated with DMSO or 1 mol/L RA were infected with adenovirus-expressing full-length mouse Sox9 (Ad-Sox9) or GFP (Ad-GFP). Consistent with Figure 6A , negligible von Kossa reactivity is observed in DMSO-treated Figure 6 . RA treatment reduces Sox9 expression and promotes matrix mineralization. Cultured E10 chick mitral valve explants were treated with DMSO (A, C, and E) or RA (B, D, and F) and subjected to infection with Ad-GFP (C and D) or Ad-Sox9 (E and F), or cultured without virus (A and B) . G, Quantitation of von Kossa reactivity in treated explants, normalized to area (Alcian blue staining). *PϽ0.05 compared to relative DMSO control; #PϽ0.05 compared to RA and Ad-GFP infection. H, Normalized fold change in endogenous chicken Sox9 (cSox9) and adenoviral mouse Sox9 (Ad mSox9). *PϽ0.05 compared to respective DMSO-or RA-treated controls. #PϽ0.05 compared to DMSOϩAd-GFP.
explants infected with Ad-GFP ( Figure 6C ) or Ad-Sox9 ( Figure  6E ). In DMSO-treated explants, endogenous chicken Sox9 expression does not change, whereas mouse Sox9 expression is significantly increased in Ad-Sox9 -infected explants ( Figure  6H ), confirming targeted overexpression. As expected, RA treatment in Ad-GFP-infected explants significantly increases von Kossa reactivity (Ͼ30%) ( Figure 6D ) and decreases Sox9 expression ( Figure 6H ) compared to DMSO controls infected with Ad-GFP ( Figure 6C and 6H) . Notably, RA treatment in Ad-Sox9 -infected explants ( Figure 6F ) does not increase von Kossa reactivity to levels observed in RA-treated Ad-GFPinfected ( Figure 6D ) explants. These findings suggest that increased Sox9 expression prevents RA-induced heart valve calcification in vitro, supporting a direct and causative role for reduced Sox9 function in promoting calcific valve phenotypes.
Discussion
Identification of signaling pathways that mediate disease onset or progression is critical for the development of new treatments for calcific valvular disease. Here, we present findings from a mouse model with targeted loss of Sox9 function during valve development that displays increased susceptibility to calcific valve phenotypes in adulthood. This is marked by the appearance of calcific lesions and increased expression of osteogenic genes including Runx2 in valve leaflets from adult Table I ). The ability of Sox9 deficiency to directly promote valvular calcification is supported by increased von Kossa reactivity following Sox9 knockdown in murine valve explants in vitro. Furthermore, similar calcification is observed following RA treatment in vitro, and overexpression of Sox9 is sufficient to attenuate RA-induced calcification. Collectively, these findings suggest that Sox9 plays important roles in maintaining connective tissue homeostasis in mature heart valve structures and provide insights into a genetic basis for calcific valvular disease.
Sox9 Is Required to Maintain Heart Valve Connective Tissue Homeostasis
In mature heart valves, ECM composition and organization are essential for maintaining valve structure and function. 3, 4, 36 Previous studies have shown that mature valve leaflets are rich in proteoglycans and express markers characteristic of cartilage tissue. 4 Furthermore, our group has shown that cartilage-associated gene expression in developing heart valves requires Sox9, similar to findings in chondrogenic systems. 20, 22, 54, 55 These findings highlight an important role for Sox9 in establishing the desired connective tissue composition in normal heart valves. In this present study, we show that reduced Sox9 function leads to ectopic formation of calcified matrix and therefore highlight an additional role for Sox9 in maintaining connective tissue homeostasis of mature valves. However, the mechanisms of Sox9 function in these processes are not clear, but our findings suggest that Sox9 plays pivotal roles in promoting cartilage-like phenotypes and preventing osteogenic processes in normal heart valve structures. Therefore, dysregulation of Sox9 function likely has profound effects in promoting proteoglycan or osteogenic-related valvular disease associated with "floppy" or "stiffened" valve function, respectively.
Sox9 Function and Calcific Valvular Disease
Sox9
fl/ϩ ;Col2a1-cre mice develop calcific lesions on the surface of heart valve leaflets adjacent to blood blow, therefore highlighting similarities between our mutant mouse model and human calcified valvular disease. 9 However, it is appreciated that the gross changes in ECM organization observed in human calcified valves cannot be thoroughly analyzed in this model because of size limitations of rodent heart valves. 3 At the molecular level, we again observe similarities with clinical pathology, including increased expression of bone-associated genes including Runx2 and downstream osteogenic target genes. 7, 50 The underlying etiology that promotes pathological bone signaling in heart valves are not understood, but recent studies have identified NOTCH1 mutations in patients with bicuspid aortic valve and aortic valve calcification. 14 Interestingly, both NOTCH1 and SOX9 have been shown to repress RUNX2 activity. 14, 25 Therefore, one might predict that the osteogenic phenotypes observed in Sox9 fl/ϩ ;Col2a1-cre mice are attributable to lost repression of Runx2. However, Notch1 expression was not significantly different in heart valves from Sox9 fl/ϩ ;Col2a1-cre mice, and therefore interactions between Sox9 and Notch signaling on Runx2 activity cannot be discerned.
Unlike calcified human valves, where pathological calcification is associated with functional defects including stenosis, heart valve function in Sox9 fl/ϩ ;Col2a1-cre mice is normal, and using conventional echocardiography, valve leaflet fusion was not observed. This suggests that the calcific lesion size (Ͻ4%) within the valve leaflet is not sufficient to affect mechanical properties of the valve at 12 months of age. Studies in mouse models susceptible to valve calcification have effectively aggravated phenotypes with additional exposure to known clinical risk factors including hypercholesterolemia and renal dysfunction, highlighting the multifactorial nature of this disease and therefore exposing Sox9 fl/ϩ ; Col2a1-cre mice to such factors would be a plausible approach for future studies. 53, 56, 57 The RA-Sox9 Pathway Is a Potential Therapeutic
Target for Treatment or Prevention of Calcific Valvular Disease
Previous approaches in the treatment of calcific valvular disease have focused on treating underlying risk factors. However, clinical trials using lipid-lowering therapies have been inconclusive and patient outcomes are not improved. 58 -60 Therefore, alternative strategies are needed to improve disease prognosis and insights will likely be gained by targeting signaling pathways active during the onset and progression of calcific disease. Our findings suggest that RA signaling regulates Sox9 function to promote osteogenic processes in mature heart valves, highlighting RA-Sox9 signaling as a potential target for alternative therapeutic approaches. Manipulation of the RA signaling pathway has already proven pharmacologically effective in the treatment of several bone-associated pathologies, including the use of small-molecule RA inhibitors such as antiosteogenic agents. [61] [62] [63] Therefore, future work investigating the benefits of retinoid pathway antagonism in the prevention or treatment of calcific valvular disease is warranted. Collectively, our studies identify a previously unappreciated role for Sox9 function in maintaining connective tissue homeostasis in mature heart valve structures. In addition, there is evidence to suggest that reduced Sox9 function during embryonic development later leads to calcific valvular disease manifested in the adult.
What New Information Does This Article Contribute?
• Reduced Sox9 function promotes calcific valve phenotypes in vitro and in vivo.
• Heart valve calcification in mice with reduced Sox9 function is associated with increased osteogenic signaling and activation of inflammatory and extracellular matrix processes.
• Retinoic acid treatment promotes calcific valve phenotypes that can be rescued by Sox9 overexpression.
Calcification of heart valve structures is the most common form of valvular disease and most often results in surgical replacement. Despite the significance, the mechanisms that promote disease onset and progression are largely unknown. In this present study, we have identified that reduced Sox9 function in a subset of type II collagen-derived valve cells during embryonic development promotes calcific valve phenotypes in vivo. This pathological state is associated with increased signaling of genes active during bone development and activation of inflammatory and matrix remodeling processes in calcified valves from Sox9 mutant mice. Furthermore, we have identified retinoic acid as an upstream repressor of Sox9 function in promoting calcification in vitro. This study generated a mouse model of human pathology and identified a novel genetic-based mechanism for calcific valve disease. Findings from this study provide insights into the molecular mechanisms that promote the onset of heart valve calcification that will undoubtedly contribute to the development of alternative therapeutic strategies.
